Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer-Reference-Cited by-同舟云学术

Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer

Published:2020-07-08 Issue:1 Volume:31 Page:1-9
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Ingle James N.,Kalari Krishna R.,Barman Poulami,Shepherd Lois E.,Ellis Matthew J.,Goss Paul E.,Buzdar Aman U.,Robson Mark E.,Cairns Junmei,Carlson Erin E.,Eyman Casey Abraham,Hoskin Tanya L.,Goodnature Barbara A.,Haddad Tufia C.,Goetz Matthew P.,Weinshilboum Richard M.,Wang Liewei

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference26 articles.

1. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.;Ingle;Steroids,2011

2. Aromatase inhibitors vs tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials.;Lancet,2015

3. Aromatase inhibitors for therapy of advanced breast cancer.;Ingle;J Steroid Biochem Mol Biol,2005

4. Exemestane for breast-cancer prevention in postmenopausal women.;Goss;N Engl J Med,2011

5. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.;Cuzick;Lancet,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy;Breast Cancer Research;2024-07-04

2. Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial;Clinical Cancer Research;2024-05-15